[voxelotor对血红蛋白电泳和色谱谱的影响]。

IF 0.4 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY
Soraya Fellahi, Nadir Mouri, Baptiste Giraud, Suella Martino, Gonzalo de Luna, Mehdi Sakka, Philippe Joly, Jean-Philippe Bastard, Frédéric Galacteros, Stéphane Moutereau
{"title":"[voxelotor对血红蛋白电泳和色谱谱的影响]。","authors":"Soraya Fellahi,&nbsp;Nadir Mouri,&nbsp;Baptiste Giraud,&nbsp;Suella Martino,&nbsp;Gonzalo de Luna,&nbsp;Mehdi Sakka,&nbsp;Philippe Joly,&nbsp;Jean-Philippe Bastard,&nbsp;Frédéric Galacteros,&nbsp;Stéphane Moutereau","doi":"10.1684/abc.2023.1814","DOIUrl":null,"url":null,"abstract":"<p><p>Voxelotor (GBT440, OXBRYTA®) appeared recently as one of the possible treatments for sickle cell disease. This molecule, by binding the alpha globin of hemoglobin, causes hyperaffinity of the latter for oxygen and reduces its polymerization properties. Several therapeutic trials have been able to show its effectiveness on certain aspects of sickle cell disease; thus, the french HAS (High Authority of Health) college issued an early access authorization and, since 2021, this treatment can be offered to patients under a temporary authorization for use. Consequently, the laboratories that carry out the biological monitoring of sickle cell patients will be confronted with new profiles characteristic of the presence of hemoglobin combined with GBT440. This work presents a collection of images obtained by different techniques: HPLC, capillary electrophoresis, isoelectrofocusing, alkaline gel and acid agar gel electrophoresis in transfused or non-transfused sickle cell disease patients. The ability to observe the presence of GBT440 by these analyzes could be useful in order to characterize the therapeutic follow-up of patients.</p>","PeriodicalId":7892,"journal":{"name":"Annales de biologie clinique","volume":"81 3","pages":"320-326"},"PeriodicalIF":0.4000,"publicationDate":"2023-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Impact of voxelotor on hemoglobin electrophoretic and chromatographic profiles].\",\"authors\":\"Soraya Fellahi,&nbsp;Nadir Mouri,&nbsp;Baptiste Giraud,&nbsp;Suella Martino,&nbsp;Gonzalo de Luna,&nbsp;Mehdi Sakka,&nbsp;Philippe Joly,&nbsp;Jean-Philippe Bastard,&nbsp;Frédéric Galacteros,&nbsp;Stéphane Moutereau\",\"doi\":\"10.1684/abc.2023.1814\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Voxelotor (GBT440, OXBRYTA®) appeared recently as one of the possible treatments for sickle cell disease. This molecule, by binding the alpha globin of hemoglobin, causes hyperaffinity of the latter for oxygen and reduces its polymerization properties. Several therapeutic trials have been able to show its effectiveness on certain aspects of sickle cell disease; thus, the french HAS (High Authority of Health) college issued an early access authorization and, since 2021, this treatment can be offered to patients under a temporary authorization for use. Consequently, the laboratories that carry out the biological monitoring of sickle cell patients will be confronted with new profiles characteristic of the presence of hemoglobin combined with GBT440. This work presents a collection of images obtained by different techniques: HPLC, capillary electrophoresis, isoelectrofocusing, alkaline gel and acid agar gel electrophoresis in transfused or non-transfused sickle cell disease patients. The ability to observe the presence of GBT440 by these analyzes could be useful in order to characterize the therapeutic follow-up of patients.</p>\",\"PeriodicalId\":7892,\"journal\":{\"name\":\"Annales de biologie clinique\",\"volume\":\"81 3\",\"pages\":\"320-326\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales de biologie clinique\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1684/abc.2023.1814\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/abc.2023.1814","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Voxelotor (GBT440, OXBRYTA®)最近作为镰状细胞病的可能治疗方法之一出现。这个分子,通过结合血红蛋白的α -珠蛋白,导致后者对氧的高亲和力,并降低其聚合性能。几项治疗试验已经能够显示其对镰状细胞病某些方面的有效性;因此,法国卫生高等管理局(HAS)学院颁发了早期使用许可,自2021年起,可以在临时许可下向患者提供这种治疗。因此,对镰状细胞患者进行生物监测的实验室将面临血红蛋白与GBT440联合存在的新特征。这项工作介绍了通过不同技术获得的图像集合:高效液相色谱,毛细管电泳,等电聚焦,碱性凝胶和酸性琼脂凝胶电泳在输注或非输注镰状细胞病患者。通过这些分析观察到GBT440存在的能力对于表征患者的治疗随访是有用的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Impact of voxelotor on hemoglobin electrophoretic and chromatographic profiles].

Voxelotor (GBT440, OXBRYTA®) appeared recently as one of the possible treatments for sickle cell disease. This molecule, by binding the alpha globin of hemoglobin, causes hyperaffinity of the latter for oxygen and reduces its polymerization properties. Several therapeutic trials have been able to show its effectiveness on certain aspects of sickle cell disease; thus, the french HAS (High Authority of Health) college issued an early access authorization and, since 2021, this treatment can be offered to patients under a temporary authorization for use. Consequently, the laboratories that carry out the biological monitoring of sickle cell patients will be confronted with new profiles characteristic of the presence of hemoglobin combined with GBT440. This work presents a collection of images obtained by different techniques: HPLC, capillary electrophoresis, isoelectrofocusing, alkaline gel and acid agar gel electrophoresis in transfused or non-transfused sickle cell disease patients. The ability to observe the presence of GBT440 by these analyzes could be useful in order to characterize the therapeutic follow-up of patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annales de biologie clinique
Annales de biologie clinique 医学-医学:研究与实验
CiteScore
0.80
自引率
20.00%
发文量
53
审稿时长
6-12 weeks
期刊介绍: Multidisciplinary information with direct relevance to everyday practice Annales de Biologie Clinique, the official journal of the French Society of Clinical Biology (SFBC), supports biologists in areas including continuing education, laboratory accreditation and technique validation. With original articles, abstracts and accounts of everyday practice, the journal provides details of advances in knowledge, techniques and equipment, as well as a forum for discussion open to the entire community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信